AP2369A - Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. - Google Patents

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Info

Publication number: AP2369A
Authority: AP; ARIPO
Prior art keywords: pyrrolopyrazoles; carbonylamino; kinase inhibitors; potent kinase; potent
Prior art date: 2005-12-21

Application number

AP2008004506A

Other languages

English (en)

Other versions

AP2008004506A0 (en

Inventor

Liming Dong

Chuangxing Guo

Yufeng Hong

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-21

Filing date

2006-12-12

Publication date

2012-02-29

2006-12-12 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-06-30 Publication of AP2008004506A0 publication Critical patent/AP2008004506A0/xx

2012-02-29 Application granted granted Critical

2012-02-29 Publication of AP2369A publication Critical patent/AP2369A/xx

Links

XPBFIMLMVNXIIB-UHFFFAOYSA-N 3-isocyanatopyrrolo[3,2-c]pyrazole Chemical class N1=CC=C2N=NC(N=C=O)=C21 XPBFIMLMVNXIIB-UHFFFAOYSA-N 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
230000003389 potentiating effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AP2008004506A 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. AP2369A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US75334905P	2005-12-21	2005-12-21
US86493206P	2006-11-08	2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en)	2005-12-21	2006-12-12	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (2)

Publication Number	Publication Date
AP2008004506A0 AP2008004506A0 (en)	2008-06-30
AP2369A true AP2369A (en)	2012-02-29

Family

ID=38189022

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2008004506A AP2369A (en)	2005-12-21	2006-12-12	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Country Status (26)

Country	Link
US (1)	US7884117B2 (es)
EP (1)	EP1979356B1 (es)
JP (1)	JP4635089B2 (es)
KR (1)	KR101029167B1 (es)
AP (1)	AP2369A (es)
AU (1)	AU2006327866B2 (es)
BR (1)	BRPI0620354A2 (es)
CA (1)	CA2634381C (es)
CR (1)	CR10094A (es)
CU (1)	CU23751B7 (es)
DK (1)	DK1979356T3 (es)
EA (1)	EA015513B1 (es)
EC (1)	ECSP088558A (es)
ES (1)	ES2435405T3 (es)
GE (1)	GEP20104974B (es)
HR (1)	HRP20130976T1 (es)
IL (1)	IL191776A (es)
MA (1)	MA30076B1 (es)
ME (1)	MEP0808A (es)
MY (1)	MY151455A (es)
NO (1)	NO20082482L (es)
NZ (1)	NZ568692A (es)
PL (1)	PL1979356T3 (es)
PT (1)	PT1979356E (es)
RS (2)	RS53029B (es)
WO (1)	WO2007072153A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL385265A1 (pl) *	2008-05-23	2009-12-07	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
US9394333B2 (en)	2008-12-02	2016-07-19	Wave Life Sciences Japan	Method for the synthesis of phosphorus atom modified nucleic acids
MX342945B (es)	2009-07-06	2016-10-18	Ontorii Inc *	Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
US9180127B2 (en)	2009-12-29	2015-11-10	Dana-Farber Cancer Institute, Inc.	Type II Raf kinase inhibitors
DK2620428T3 (da) *	2010-09-24	2019-07-01	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
EP2640369A1 (en)	2010-11-17	2013-09-25	F.Hoffmann-La Roche Ag	Methods of treating tumors
US8771682B2 (en)	2011-04-26	2014-07-08	Technische Universtität Dresden	Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
US9605019B2 (en)	2011-07-19	2017-03-28	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
CA2856291C (en)	2011-11-17	2020-08-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
EP2844248A1 (en)	2012-03-16	2015-03-11	F. Hoffmann-La Roche AG	Methods of treating melanoma with pak1 inhibitors
SG11201500243WA (en)	2012-07-13	2015-04-29	Shin Nippon Biomedical Lab Ltd	Chiral nucleic acid adjuvant
KR20240148947A (ko)	2012-07-13	2024-10-11	웨이브 라이프 사이언시스 리미티드	키랄 제어
SG11201500239VA (en)	2012-07-13	2015-03-30	Wave Life Sciences Japan	Asymmetric auxiliary group
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
US9758522B2 (en)	2012-10-19	2017-09-12	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
US10047070B2 (en)	2013-10-18	2018-08-14	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2014337122B2 (en)	2013-10-18	2019-01-03	Dana-Farber Cancer Institute, Inc.	Heteroaromatic compounds useful for the treatment of proliferative diseases
EP3095460A4 (en)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es)	2014-01-16	2022-07-08	Wave Life Sciences Ltd	Diseño quiral
US9862688B2 (en)	2014-04-23	2018-01-09	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
CA2966164C (en)	2014-10-31	2023-10-17	Ube Industries, Ltd.	Substituted dihydropyrrolopyrazole compound
EP3236959B1 (en)	2014-12-23	2025-09-24	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en)	2015-03-27	2021-03-25	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
US10702527B2 (en)	2015-06-12	2020-07-07	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
EP3309163A4 (en)	2015-06-15	2019-01-09	UBE Industries, Ltd.	SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
EP4019515A1 (en)	2015-09-09	2022-06-29	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en)	2016-02-23	2017-08-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
JP7590185B2 (ja)	2018-06-25	2024-11-26	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
EP3885347B1 (en)	2018-11-14	2023-11-22	UBE Corporation	Dihydropyrrolopyrazole derivative
AU2019413694B2 (en) *	2018-12-28	2025-03-20	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3956446A1 (en)	2019-04-17	2022-02-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
JP7769388B2 (ja)	2019-12-12	2025-11-13	ティンセラピューティクス，インコーポレイテッド	聴覚損失の予防及び治療のための組成物及び方法
WO2021198511A1 (en)	2020-04-03	2021-10-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en)	2020-07-08	2022-01-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of infectious diseases
WO2024261302A1 (en)	2023-06-22	2024-12-26	Institut National de la Santé et de la Recherche Médicale	Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en)	2023-10-09	2025-04-17	Institut National de la Santé et de la Recherche Médicale	Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002012242A2 (en) *	2000-08-10	2002-02-14	Pharmacia Italia S.P.A.	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) *	2002-12-19	2004-07-08	Pharmacia Italia Spa	Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) *	2003-09-23	2005-04-07	Vertex Pharmaceuticals Incorporated	Pyrazolopyrrole derivatives as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003244649A1 (en)	2002-07-25	2004-02-23	Pharmacia Italia Spa	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0229526D0 (en)	2002-12-19	2003-01-22	Astrazeneca Ab	Chemical compounds
SI1838718T1 (sl)	2005-01-10	2011-08-31	Pfizer	Pirolopirazoli, zmogljivi inhibitorji kinaze

2006
- 2006-12-12 ME MEP-08/08A patent/MEP0808A/xx unknown
- 2006-12-12 EP EP06831731.2A patent/EP1979356B1/en active Active
- 2006-12-12 GE GEAP200610777A patent/GEP20104974B/en unknown
- 2006-12-12 WO PCT/IB2006/003646 patent/WO2007072153A2/en not_active Ceased
- 2006-12-12 EA EA200801291A patent/EA015513B1/ru not_active IP Right Cessation
- 2006-12-12 BR BRPI0620354-0A patent/BRPI0620354A2/pt not_active IP Right Cessation
- 2006-12-12 NZ NZ568692A patent/NZ568692A/en not_active IP Right Cessation
- 2006-12-12 AP AP2008004506A patent/AP2369A/xx active
- 2006-12-12 DK DK06831731.2T patent/DK1979356T3/da active
- 2006-12-12 RS RS20130498A patent/RS53029B/sr unknown
- 2006-12-12 AU AU2006327866A patent/AU2006327866B2/en not_active Ceased
- 2006-12-12 US US12/158,241 patent/US7884117B2/en not_active Expired - Fee Related
- 2006-12-12 CA CA2634381A patent/CA2634381C/en not_active Expired - Fee Related
- 2006-12-12 PL PL06831731T patent/PL1979356T3/pl unknown
- 2006-12-12 RS RSP-2008/0281A patent/RS20080281A/sr unknown
- 2006-12-12 ES ES06831731T patent/ES2435405T3/es active Active
- 2006-12-12 JP JP2008546667A patent/JP4635089B2/ja not_active Expired - Fee Related
- 2006-12-12 PT PT68317312T patent/PT1979356E/pt unknown
- 2006-12-12 MY MYPI20082267 patent/MY151455A/en unknown
- 2006-12-12 HR HRP20130976TT patent/HRP20130976T1/hr unknown
- 2006-12-12 KR KR1020087014963A patent/KR101029167B1/ko not_active Expired - Fee Related
2008
- 2008-05-27 IL IL191776A patent/IL191776A/en not_active IP Right Cessation
- 2008-06-02 NO NO20082482A patent/NO20082482L/no not_active Application Discontinuation
- 2008-06-18 EC EC2008008558A patent/ECSP088558A/es unknown
- 2008-06-19 CU CU20080115A patent/CU23751B7/es active IP Right Grant
- 2008-06-20 MA MA31060A patent/MA30076B1/fr unknown
- 2008-06-20 CR CR10094A patent/CR10094A/es unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002012242A2 (en) *	2000-08-10	2002-02-14	Pharmacia Italia S.P.A.	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) *	2002-12-19	2004-07-08	Pharmacia Italia Spa	Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) *	2003-09-23	2005-04-07	Vertex Pharmaceuticals Incorporated	Pyrazolopyrrole derivatives as protein kinase inhibitors

Also Published As

Publication number	Publication date
PL1979356T3 (pl)	2014-01-31
CU20080115A7 (es)	2010-08-30
JP2009520805A (ja)	2009-05-28
ES2435405T3 (es)	2013-12-19
IL191776A0 (en)	2008-12-29
CU23751B7 (es)	2012-01-31
AU2006327866A1 (en)	2007-06-28
WO2007072153A2 (en)	2007-06-28
PT1979356E (pt)	2013-11-21
RS20080281A (sr)	2009-09-08
CR10094A (es)	2008-08-01
BRPI0620354A2 (pt)	2011-11-08
IL191776A (en)	2013-03-24
ME00006B (me)	2010-02-10
JP4635089B2 (ja)	2011-02-16
WO2007072153A8 (en)	2008-08-14
NZ568692A (en)	2011-07-29
HRP20130976T1 (hr)	2013-11-22
AU2006327866B2 (en)	2012-06-14
EP1979356B1 (en)	2013-09-18
US7884117B2 (en)	2011-02-08
MY151455A (en)	2014-05-30
MEP0808A (xx)	2010-02-10
EA015513B1 (ru)	2011-08-30
HK1128290A1 (en)	2009-10-23
ECSP088558A (es)	2008-07-30
WO2007072153A3 (en)	2007-10-25
CA2634381A1 (en)	2007-06-28
CA2634381C (en)	2011-03-08
EP1979356A2 (en)	2008-10-15
DK1979356T3 (da)	2013-11-18
EA200801291A1 (ru)	2008-12-30
US20090318440A1 (en)	2009-12-24
NO20082482L (no)	2008-07-02
KR101029167B1 (ko)	2011-04-12
RS53029B (sr)	2014-04-30
KR20080080567A (ko)	2008-09-04
MA30076B1 (fr)	2008-12-01
AP2008004506A0 (en)	2008-06-30
GEP20104974B (en)	2010-04-26

Publication	Publication Date	Title
AP2369A (en)	2012-02-29	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
IL184275A0 (en)	2007-10-31	Pyrrolopyrazoles, potent kinase inhibitors
EG25264A (en)	2011-11-30	Biphenyl-n-(4-pyridyl) methylsulfonamides.
IL190078A0 (en)	2008-08-07	Kinase inhibitors
EG25271A (en)	2011-12-04	Fungicidal combinations.
GB2424882B (en)	2008-08-06	Selective kinase inhibitors
SI2270008T1 (sl)	2013-01-31	8-heteroaril-3-alkil-1,3-dihidro-imidazo(4,5-c)kinolin-2-oni kot inhibitorji PI-3 kinaz
IL192033A0 (en)	2008-12-29	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AP2006003659A0 (en)	2006-06-30	Azabenzofuran substituted thioureas, inhibitors ofviral replication
AP2281A (en)	2011-10-31	Novel compounds.
PL1943243T3 (pl)	2011-05-31	Inhibitory kinazy
ZA200805028B (en)	2009-12-30	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
AP2337A (en)	2011-12-14	Motilide compounds.
AP2006003791A0 (en)	2006-10-31	1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
ZA200804667B (en)	2010-05-26	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NL1031384A1 (nl)	2006-09-20	Gesubstitueerde aryl-1,4-pyrazinederivaten.
GB0505823D0 (en)	2005-04-27	Boardmate, boardmate adjustable
GB0504761D0 (en)	2005-04-13	Alfatie, Coliawel, Omaatie
ITRM20050033U1 (it)	2006-09-16	Semicabina per fumatori.
ITTO20050072U1 (it)	2006-12-01	Armadio-espositore, particolarmente per tabaccherie
ZA200803287B (en)	2009-10-28	Kinase inhibitors
IL189985A0 (en)	2008-08-07	Kinase inhibitors
CY2449B1 (en)	2005-06-03	Multiple srengthened carton.
PL378279A1 (pl)	2007-06-11	Układ do osuszania gazów zwłaszcza dla komór klimatycznych
HK1122294A (en)	2009-05-15	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors